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Abstract
Background: One quarter to one third of patients eligible for systemic thrombolysis are on antiplatelet therapy at
presentation. In this study, we aimed to assess the safety and efficacy of intravenous thrombolysis in stroke patients
on prescribed antiplatelet therapy in the WAKE-UP trial.
Methods: WAKE-UP was a multicenter, randomized, double-blind, placebo-controlled clinical trial to study the
efficacy and safety of MRI-guided intravenous thrombolysis with alteplase in patients with an acute stroke of
unknown onset time. The medication history of all patients randomized in the WAKE-UP trial was documented. The
primary safety outcome was any sign of hemorrhagic transformation on follow-up MRI. The primary efficacy
outcome was favorable functional outcome defined by a score of 0–1 on the modified Rankin scale at 90 days after
stroke, adjusted for age and baseline stroke severity. Logistic regression models were fitted to study the association
of prior antiplatelet treatment with outcome and treatment effect of intravenous alteplase.
Results: Of 503 randomized patients, 164 (32.6%) were on antiplatelet treatment. Patients on antiplatelet treatment
were older (70.3 vs. 62.8 years, p < 0.001), and more frequently had a history of hypertension, atrial fibrillation, diabetes,
hypercholesterolemia, and previous stroke or transient ischaemic attack. Rates of symptomatic intracranial hemorrhage
and hemorrhagic transformation on follow-up imaging did not differ between patients with and without antiplatelet
treatment. Patients on prior antiplatelet treatment were less likely to achieve a favorable outcome (37.3% vs. 52.6%, p =
0.014), but there was no interaction of prior antiplatelet treatment with intravenous alteplase concerning favorable
outcome (p = 0.355). Intravenous alteplase was associated with higher rates of favorable outcome in patients on prior
antiplatelet treatment with an adjusted odds ratio of 2.106 (95% CI 1.047–4.236).
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Conclusions: Treatment benefit of intravenous alteplase and rates of post-treatment hemorrhagic transformation were
not modified by prior antiplatelet intake among MRI-selected patients with unknown onset stroke. Worse functional
outcome in patients on antiplatelets may result from a higher load of cardiovascular co-morbidities in these patients.
Keywords: Ischemic stroke, Alteplase, Thrombolysis, Recombinant human tissue plasminogen activator, Rt-PA, Aspirin,
Clopidogrel, Hemorrhagic transformation, Antiplatelet, WAKE UP
Background
Approximately one quarter to one third of all patients
receiving intravenous thrombolytic therapy with alte-
plase (recombinant human tissue plasminogen activator,
rt-PA) for the treatment of acute ischemic stroke are on
prescribed antiplatelet treatment (APT) [7, 10, 15]. The
fact that both antiplatelets and alteplase interfere sub-
stantially with the natural hemostasis raises concern
about an increased risk of hemorrhagic complications,
and in the ARTIS trial a high rate of symptomatic intra-
cerebral hemorrhage (sICH) was observed with simul-
taneous administration of intravenous alteplase and
aspirin [20]. However, neither in current guidelines, nor
in clinical practice, is prior APT considered as an exclu-
sion criterion to treatment with alteplase [9, 19].
Several studies have explored the potential association
of antiplatelet treatment with hemorrhagic complica-
tions in the context of acute thrombolysis for stroke. In
this context, it’s important to distinguish between differ-
ent categories of intracranial hemorrhage following is-
chemic stroke. Whereas sICH and parenchymal
hemorrhage type 2 (PH2) seem to be related to biologic
effects of alteplase and clinically relevant for the patients,
the haemorrhagic transformation of infarcted brain tis-
sue might just be an epiphenomenon of ischemic dam-
age and reperfusion [14, 16]. Recent meta-analyses
unanimously found APT to be significantly associated
with higher risk of subsequent intracerebral hemorrhage
(ICH) or sICH in patients treated with rt-PA. In con-
trast, evidence regarding a possible interaction as to
functional outcome remains contradictory [4, 7, 15, 17].
WAKE-UP was a randomized, double-blind, placebo-
controlled trial on efficacy and safety of MRI-based
thrombolysis in wake-up stroke [12]. The trial protocol
comprised follow-up MRI at 22–36 h, enabling the de-
tection of even small and asymptomatic ICH following
thrombolysis. In the present secondary post hoc analysis
of the WAKE-UP trial data, we aimed at studying the ef-




Inclusion criteria for the WAKE-UP trial comprised the
mismatch between an acute ischemic lesion visible on
diffusion weighted imaging (DWI) and no corresponding
marked parenchymal hyperintensity on fluid-attenuated
inversion recovery (FLAIR). Preceding studies endorsed
this mismatch as a surrogate marker of lesion age, indi-
cating that the stroke onset most likely lies within 4.5 h
[13]. All patients or their legal representatives provided
written informed consent according to national and local
regulations and the competent authorities for each
study site and the corresponding ethics committee ap-
proved the trial. Analysis of MR images and assess-
ment of hemorrhagic transformation was done
centrally by a central image reading board. The de-
tailed trial protocol was published together with its
main results [12]. For the present post hoc analysis,
all data on the medical history of patients randomized
in WAKE-UP was reviewed to identify participants
with medication history that included current APT
prescription. The agents screened for were as follows:
Aspirin, Clopidogrel, Dipyridamol, Triflusal (Single-
non-aspirin), Ticagrelor, Prasugrel, Ticlopidine and
Eptfibatide. Both single and dual therapy were separ-
ately recorded. Furthermore, demographic characteris-
tics and clinical data at baseline and follow-up were
collected for statistical analysis.
Outcome measures and endpoints
Primary safety outcome was the occurrence of any
hemorrhagic transformation on follow-up imaging 22–
36 h after treatment, corresponding to HI-1, HI-2, PH-1
and PH-2 in the Heidelberg bleeding classification [16].
The definition of sICH was according to the Safe Imple-
mentation of Thrombolysis in Stroke Monitoring Study
(SITS–MOST) local or remote PH-2 plus neurologic de-
terioration, as indicated by a score on the NIHSS that
was higher by 4 points or more than the baseline value
or the lowest value between baseline and 24 h, or
hemorrhage leading to death. The evaluation of the effi-
cacy results was based on the clinical endpoints as de-
fined in the WAKE-UP study, whereby clinical outcome
was assessed at 90 days after stroke. The primary end-
point was favorable outcome defined as a score of 0–1
on the modified Rankin scale (mRS). Secondary end-
point was a shift towards a better functional outcome
across the entire range of the mRS (“shift analysis”).
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Statistical analysis
At first, baseline characteristics between patients with
and without APT prescription were compared. The stat-
istical analyses of treatment effects were performed in
the intention-to-treat population for all patients with
available information for clinical endpoints.
For the safety and primary efficacy variables, we calcu-
lated unconditional logistic regression models to esti-
mate the odds ratio and its 95% confidence interval (CI).
The categorical shift in the distribution of mRS scores
was analyzed by fitting a proportional-odds logistic re-
gression model. To investigate the interaction between
APT and treatment effect of alteplase, an according
interaction term was included in the models. All models
fitted were adjusted for the stratification parameters age
and NIHSS at randomization. As all analyses were con-
sidered exploratory, all tests were carried out with a




Of 503 randomized patients, 164 patients (32.6%) were
on APT. Of these, 134 patients (81.7%) were pretreated
with aspirin, 34 patients (20.7%) with clopidogrel, 6 pa-
tients (3.7%) with dipyridamole, 1 patient (0.6%) with tri-
flusal, and 11 (6.7%) patients were pretreated with two
antiplatelets. For the latter, aspirin was prescribed in all
cases, combined with clopidogrel in 7 patients and with
dipyridamol in 4 patients. Patients on APT were older
(mean age 70.3 vs. 62.8 years, p < 0.001), and were more
likely to have a medical history of smoking, hyperten-
sion, atrial fibrillation, diabetes mellitus type II, hyper-
cholesterolemia, previous ischemic stroke and transient
ischemic attacks (all p < 0.001, see Table 1). Consistent
with this, patients with prior APT showed higher rates
of simultaneous pretreatment with antidiabetic drugs,
antihypertensives, and statins. Other baseline character-
istics were comparable between patients with and with-
out prior APT.
Information on the primary and secondary efficacy
endpoints was available for 490 participants. Of these,
246 and 244 were randomized to treatment with alte-
plase and placebo, respectively. The proportion of pa-
tients on prior APT in the alteplase group (n = 75,
30.5%) was comparable to the placebo group (n = 86,
35.2%, p = 0.290). Information on the primary safety
endpoint and the secondary safety endpoint PH-2
hemorrhage was available for 496 participants. Informa-
tion on the secondary safety endpoint sICH according to
SITS–MOST was available for 503 participants.
Safety outcomes in patients with antiplatelet
pretreatment
Prior APT was not associated with higher risk of any
radiological hemorrhagic transformation (24.5% vs
23.7%, adjusted OR 0.84, 95% CI 0.63–1.36; p = 0.478).
There was no significant difference between either
groups regarding the occurrence of sICH (2.4% vs 0.6%;
adjusted OR 2.84, 95% CI 0.50–16.05; p = 0.238). In the
group with APT, 5 patients (3.1%) showed PH-2
hemorrhage on follow-up imaging, compared to 6 pa-
tients (1.8%) in the group of patients without prior APT
(adjusted OR 1.17, 95% CI 0.34–4.09; p = 0.806).
Interaction of antiplatelet pretreatment and treatment
safety of alteplase
The general low frequency of sICH and PH-2
hemorrhage in our cohort did not allow for statistical
modelling. Treatment with alteplase was associated with
Table 1 Baseline characteristics of patients with ischemic stroke and unknown symptom onset
Variable Prior APT (n = 164) No prior APT (n = 339) P Value
Age, mean (SD), years 70.3 (8.2) 62.8 (12.1) < 0.001
Female sex, No. (%) 60 (36.6) 118 (34.8) 0.692
Time between last seen well and symptom recognition, median (IQR), hours 7.52 (5.00–8.50) 7.00 (4.67–9.50) 0.085
Medical history/risk factors, No. (%)
Arterial hypertension 120 (73.2) 146 (43.1) < 0.001
Diabetes mellitus 44 (26.8) 38 (11.2) < 0.001
Hypercholesterolemia 98 (59.8) 80 (23.6) < 0.001
Atrial fibrillation 27 (16.5) 32 (9.4) 0.010
History of ischemic stroke 52 (31.7) 16 (4.7) < 0.001
History of TIA 17 (10.4) 6 (1.8) < 0.001
Current or former smoker 94 (58) 162 (50) 0.009
NIHSS score, median (IQR) 6 (4–12) 5 (4–9) 0.104
DWI lesion volume at baseline, median (IQR), ml 2.28 (0.80–9.61) 2.23 (0.70–7.70) 0.506
SD standard deviation, IQR interquartile range, TIA transient ischemic attack, NIHSS National Institute of Health Stroke Scale, DWI diffusion weighted imaging
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higher odds of any hemorrhagic transformation among
all randomized patients, but there was no significant
interaction effect of thrombolysis with prior APT (p =
0.631). The adjusted OR for any hemorrhagic transform-
ation with alteplase was 2.27 (95% CI 1.05–4.90) in pa-
tients with prior APT and 1.803 (95% CI 1.05–3.10) in
patients without prior APT (Fig. 1).
Interaction of antiplatelet pretreatment and treatment
effect of alteplase
Patients on APT treatment - independent of thromboly-
sis treatment group - had lower rates of favorable out-
come (37.3 vs. 52.6%; adjusted OR 0.58, 95% CI 0.38–
0.89; p = 0.014). Treatment with alteplase was associated
with higher odds of favorable outcome among all ran-
domized patients with no significant interaction between
thrombolysis and prior APT (p = 0.355). The adjusted
OR for favorable outcome with alteplase was 2.11 (95%
CI 1.05–4.24) in patients with prior APT and 1.417 (95%
CI 0.89–2.26) in patients without prior APT (Fig. 2).
Prior APT – independent of treatment group - was as-
sociated with a significant shift on the mRS towards
worse outcomes (adjusted OR 1.56, 95% CI 1.10–2.23;
p = 0.014). Treatment with alteplase was associated with
a shift on the mRS towards better functional outcome
among all randomized patients, but there was no signifi-
cant interaction of thrombolysis with prior APT (p =
0.309). The adjusted OR for a shift on the mRS towards
better outcomes with alteplase was 2.00 (95% CI 1.16–
3.46) in patients with prior APT and 1.410 (95% CI
0.95–2.09) in patients without prior APT (Fig. 3).
Discussion
In a post-hoc analysis of the WAKE-UP trial we studied
the effect of prescribed antiplatelet therapy prior to
stroke on functional outcome and safety outcomes over-
all, and on the efficacy and safety of intravenous alte-
plase in acute stroke patients with unknown time of
symptom onset. There were two main findings. First,
prior antiplatelet therapy was associated with a worse
functional outcome independent of treatment, but not
with higher rates of symptomatic intracerebral
hemorrhage or radiological signs of hemorrhagic trans-
formation. Second, pretreatment with antiplatelets did
not alter the beneficial effect or the safety of intravenous
alteplase.
In our sample about one in three patients was pre-
treated with antiplatelets, which is comparable to prior
studies on this topic in patients with known time of
symptom onset [7, 15]. This reflects the high load of car-
diovascular risk factors and co-morbidities in patients
with acute stroke, as shown by a history of arterial
hypertension in 53%, hypercholesterolemia in 35%, dia-
betes in 16%, and prior ischemic stroke in 14% of the pa-
tients in our study population. Thus, antiplatelets are
commonly prescribed among patients treated with intra-
venous thrombolysis for acute ischemic stroke, and data
on the hemorrhagic risk of this thrombolytic treatment
in these patients are helpful to inform clinical practice.
Patients on APT treatment had a worse functional
outcome in our sample – even after adjustment for age
and baseline NIHSS. This might be explained by the
higher load of co-morbidities in patients on APT and
Fig. 1 Effect of alteplase on hemorrhagic transformation. Forest plots demonstrate a significant higher chance of developing any sign of
hemorrhagic transformation during follow-up for patients treated with alteplase in both patients with prior APT and without. There was no
significant interaction in the corresponding unconditional logistic regression model
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Fig. 2 Effect of alteplase on favorable outcome. Forest plots demonstrate a higher chance of a favorable functional outcome for patients treated
with alteplase in both patients with prior APT and without. There was no significant interaction in the corresponding unconditional logistic
regression model
Fig. 3 Distribution of modified Rankin scale scores at 90 days after stroke. Distributions of scores on the modified Rankin scale show a favoring of
the alteplase group over the placebo group. Modified Rankin scale scores range from 0 to 6 (0, no symptoms; 1, no clinically significant disability;
2, slight disability; 3, moderate disability; 4, moderately severe disability; 5, severe disability; 6, death). Numbers indicate rounded proportions.
There was no significant interaction in the corresponding unconditional logistic regression model
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the known association of more severe co-morbidities
and worse functional outcome after stroke [3, 11].
Nevertheless, results from previous studies are contra-
dictory with regard to the association of pretreatment
with antiplatelets and outcome of intravenous thromb-
olysis. Some previous studies in patients with systemic
thrombolysis showed a similar association of APT with
worse functional outcome as observed in our analysis [4,
7, 10]. In contrast, a meta-analysis of randomized trials
of intravenous thrombolysis revealed no significant asso-
ciation of APT and functional outcome after correction
for age and stroke severity [15]. These contradictory
findings may result from differences in clinical charac-
teristics of the study samples and/or adjusting for vary-
ing baseline predictors.
For clinical practice, the question whether APT inter-
acts with the treatment effect of intravenous thromboly-
sis, is even more important. We did not observe any
interaction of prior APT with the treatment effect of
alteplase, neither regarding favorable outcome, nor when
considering functional outcome across the entire range
of the mRS. Intravenous alteplase had a significant bene-
ficial effect on functional outcome within the subgroup
of patients with prior APT, a finding which strongly sup-
ports the current practice that does not consider anti-
platelet treatment as a contraindication for intravenous
thrombolysis. To the best of our knowledge, this explicit
exclusion of a statistical interaction with the effects of
thrombolysis isnovel and adds substantially to the avail-
able research on pre-treatment with antiplatelets and
alteplase.
The main concern regarding pretreatment with anti-
platelets in patients receiving intravenous alteplase refers
to ICH, as there is in general an increased risk of ICH in
stroke patients on prior APT, independently of thromb-
olysis: in a Korean registry of 10,433 patients with acute
and subacute ischemic stroke, there were higher adjusted
odds of hemorrhagic transformation on MRI at presen-
tation in patients on prior APT [8].
The numbers of radiologically severe and symptomatic
ICH after intravenous thrombolysis in our study were
small, most likely an artefact of the general low severity
in the MRI-selected population of the WAKE-UP trial.
Therefore, we decided to study any hemorrhagic trans-
formation detected by follow-up MRI after 22–36 h.
Among all randomized patients, intravenous thromboly-
sis was significantly associated with a higher risk of de-
veloping any hemorrhagic transformation, which is a
well-known phenomenon linked to the biological effects
of alteplase. However, in our study patients on APT
treatment did not show higher rates of hemorrhagic
transformation, nor did prior APT interact with alteplase
with regard to the rates of hemorrhagic transformation.
These findings are in line with a metanalysis, in which
no association of APT with sICH was observed after cor-
rection for patient-level characteristics [15]. In contrast,
other previous studies found prior APT to be associated
with increased rates of ICH [10, 17] and sICH [3, 4, 6, 7,
10, 18] in patients treated with thrombolysis. Again,
these contradictory findings may result from differences
in clinical characteristics of the study samples.
There are limitations to our study. The number of
clinical relevant symptomatic intracranial hemorrhages
was small in both groups, so our study was underpow-
ered to detect differences between the groups with re-
gard to these important safety outcomes. Therefore, we
can’t exclude a potential difference in both groups, nor
can we exclude an interaction with alteplase with respect
to safety.
Moreover, due to the small numbers of patients taking
more than one antiplatelet drug, we were not able to
study the potential effect of double antiplatelet treatment
on safety and efficacy of treatment with intravenous alte-
plase in our cohort. Whereas a post-hoc analysis of the
Safe Implementation of Treatments in Stroke (SITS)
International Stroke Thrombolysis Register found a
combination of aspirin and clopidogrel associated with
higher rates of sICH, a recent meta-analysis, however,
revealed no significant risk of sICH, 3-month mortality
or worse favourable outcome after 3 months in these pa-
tients [1, 5, 6]. The numbers of patients taking other an-
tiplatelet drugs than aspirin was also small in our
cohort, so that we could not study specific risks of differ-
ent antiplatelet agents. However, a previous study with a
comparable distribution of aspirin, clopidogrel and other
antiplatelet agents found no specific differences on se-
verity of stroke at presentation, in-hospital mortality and
mRS at discharge [2].
Conclusion
To summarize, in the randomized controlled WAKE-UP
trial, treatment with intravenous alteplase was safe and
efficient in patients with unknown onset stroke on prior
antiplatelet therapy, even though the latter might be a
predictor of worse functional outcome. Intravenous
thrombolysis should not be withheld from patients with
unknown onset acute ischemic stroke on prior antiplate-
let therapy.
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